MedPath

The Experiment of Noiiglutide Injection in Type 2 Diabetes Patients

Phase 3
Recruiting
Conditions
Type 2 Diabetes
Interventions
Drug: Noiiglutide Injection
Drug: Noiiglutide Placebo
Registration Number
NCT06649773
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Brief Summary

This study aims to confirm that SHR20004 is more effective than placebo in controlling blood glucose in patients with type 2 diabetes. Evaluate the efficacy, safety, and pharmacokinetics of SHR20004 after 24 weeks of treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
124
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Noiiglutide InjectionNoiiglutide Injection-
Noiiglutide PlaceboNoiiglutide Placebo-
Primary Outcome Measures
NameTimeMethod
Changes in glycated hemoglobin (HbA1c) relative to baseline at week 24 in SHR20004 compared to placebo.Week 24
Secondary Outcome Measures
NameTimeMethod
The proportion of subjects who achieve the HbA1c target value (<7.0%)Week 24
The proportion of subjects who achieve the HbA1c target value (≤ 6.5%)Week 24
Changes in fasting plasma glucose relative to baselineWeek 24
Changes in fasting body weight relative to baselineWeek 24
Changes in plasma glucose levels relative to baseline 2 hours after mealsWeek 24
7-point self-test of blood glucose (SMBG) spectrum relative to baseline changesWeek 24
Changes in blood pressure relative to baselineWeek 24
Changes in fasting insulin relative to baselineWeek 24
Changes in C-peptide relative to baselineWeek 24
Changes in insulin levels relative to baseline 2 hours after mealsWeek 24
Changes in C-peptide levels relative to baseline 2 hours after mealsWeek 24
Adverse events (AE)Week 24
ADA of SHR20004Week 24
Nab of SHR20004Week 24
The concentration of SHR20004 in plasma at steady stateWeek 24

Trial Locations

Locations (1)

Beijing Chaoyang Hospital Affiliated to Capital

🇨🇳

Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath